Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Aduhelm
Aduhelm
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
Fierce Pharma
FDA
Biogen
Aduhelm
Alzheimer's disease
advisory committees
drug approvals
Flag link:
Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm
Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm
Endpoints
Massachusetts
Biogen
Aduhelm
legal
Flag link:
Biogen's head of neurodegeneration leaves
Biogen's head of neurodegeneration leaves
Fierce Biotech
Biogen
women executives
Aduhelm
Alzheimer's disease
Flag link:
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Flag link:
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Flag link:
Billy Dunn, FDA’s top neuroscience official to depart agency
Billy Dunn, FDA’s top neuroscience official to depart agency
RAPS.org
Billy Dunn
FDA
Neurosciences
Biogen
Aduhelm
Flag link:
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
Endpoints
Biogen
Aduhelm
FDA
Alzheimer's disease
Flag link:
Eisai learns from Biogen’s Aduhelm disaster
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
drug pricing
Flag link:
Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report
Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report
Fierce Pharma
Biogen
Aduhelm
Alzheimer's disease
FDA
US Congress
Flag link:
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
BioSpace
Eli Lilly
donanemab
clinical trials
Aduhelm
Biogen
Alzheimer's disease
Flag link:
Where Will Biogen Be in 5 Years?
Where Will Biogen Be in 5 Years?
Motley Fool
Biogen
Aduhelm
lecanemab
Alzheimer's disease
M&A
Flag link:
Medicare Part B premiums to drop 3% next year, partly due to limited Aduhelm coverage
Medicare Part B premiums to drop 3% next year, partly due to limited Aduhelm coverage
Medical Marketing and Media
Medicare
Medicare Part B
Biogen
Aduhelm
Flag link:
Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on
Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on
Fierce Pharma
Biogen
Aduhelm
Massachusetts
Boston
real estate
Cambridge
Flag link:
Aduhelm’s loss is a win for value-based drug pricing
Aduhelm’s loss is a win for value-based drug pricing
MedCity News
Biogen
Aduhelm
value-based pricing
drug pricing
Alzheimer's disease
Flag link:
Biogen deflects claims it misled shareholders about Aduhelm's success
Biogen deflects claims it misled shareholders about Aduhelm's success
Fierce Pharma
Biogen
Aduhelm
Alzheimer's disease
Flag link:
Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August?
Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August?
Fierce Biotech
Alzheimer's disease
Roche
Biogen
Eli Lilly
lecanemab
gantenerumab
Aduhelm
Flag link:
For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless
For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless
Endpoints
Biogen
Aduhelm
Alzheimer's disease
SEC
Flag link:
Biogen, targeting $1B in savings, employs 300 fewer staffers in Massachusetts than it did in September: report
Biogen, targeting $1B in savings, employs 300 fewer staffers in Massachusetts than it did in September: report
Fierce Biotech
Biogen
layoffs
Cambridge MA
Aduhelm
Flag link:
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
BioPharma Dive
Biogen
real world data
Alzheimer's disease
Medicare
Aduhelm
Flag link:
Medicare premiums to remain unchanged after Aduhelm price cut spurs review
Medicare premiums to remain unchanged after Aduhelm price cut spurs review
BioPharma Dive
Medicare
Medicare Part B
Biogen
Aduhelm
HHS
Alzheimer's disease
Flag link:
Pages
1
2
3
4
5
6
7
8
next ›
last »